NO20083717L - Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer - Google Patents
Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorerInfo
- Publication number
- NO20083717L NO20083717L NO20083717A NO20083717A NO20083717L NO 20083717 L NO20083717 L NO 20083717L NO 20083717 A NO20083717 A NO 20083717A NO 20083717 A NO20083717 A NO 20083717A NO 20083717 L NO20083717 L NO 20083717L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- pyrrolotriazine
- aniline
- prodrugs useful
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C11/00—Aliphatic unsaturated hydrocarbons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Forbindelser som har formel (I), omfattende farmasøytisk akseptable salter derav: (I), hvor minst én av X1, X2 eller X3 er (i), og en eventuell gjenværende X1, X2 eller X3 er hydrogen, som er anvendelige som kinasehemmere, hvor R1, R2, R3, R4, R5, R6, A1, A2 og m er som beskrevet her.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77985106P | 2006-03-07 | 2006-03-07 | |
PCT/US2007/063250 WO2007103839A2 (en) | 2006-03-07 | 2007-03-05 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083717L true NO20083717L (no) | 2008-10-06 |
Family
ID=38475749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083717A NO20083717L (no) | 2006-03-07 | 2008-08-29 | Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer |
Country Status (17)
Country | Link |
---|---|
US (2) | US7572795B2 (no) |
EP (1) | EP2001886A2 (no) |
JP (1) | JP2009535295A (no) |
KR (1) | KR20080107408A (no) |
CN (1) | CN101395158A (no) |
AR (1) | AR059778A1 (no) |
AU (1) | AU2007223342A1 (no) |
BR (1) | BRPI0708644A2 (no) |
CA (1) | CA2645031A1 (no) |
EA (1) | EA200801945A1 (no) |
IL (1) | IL193653A0 (no) |
MX (1) | MX2008011136A (no) |
NO (1) | NO20083717L (no) |
PE (1) | PE20080139A1 (no) |
TW (1) | TW200804390A (no) |
WO (1) | WO2007103839A2 (no) |
ZA (1) | ZA200807459B (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003231034B2 (en) * | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
JP2009535295A (ja) * | 2006-03-07 | 2009-10-01 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なピロロトリアジンアニリンプロドラッグ化合物 |
WO2009158450A1 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof |
WO2009158446A2 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof |
RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
ES2885698T3 (es) | 2009-06-25 | 2021-12-15 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos nh-ácidos |
EP2483254B1 (en) * | 2009-09-29 | 2014-08-13 | Glaxo Group Limited | Novel compounds |
CN102596921B (zh) * | 2009-09-29 | 2015-04-29 | 葛兰素集团有限公司 | 新化合物 |
EP2552922A1 (en) | 2010-03-31 | 2013-02-06 | Bristol-Myers Squibb Company | Substituted pyrrolotriazines as protein kinase inhibitors |
WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
US8901305B2 (en) * | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
WO2015035184A1 (en) | 2013-09-06 | 2015-03-12 | Xenoport, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
US10550125B2 (en) | 2015-10-20 | 2020-02-04 | Bristol-Myers Squibb Company | Prodrugs of imidazotriazine compounds as CK2 inhibitors |
CA3019137A1 (en) * | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | Soluble c5ar antagonists |
BR112020006169A2 (pt) | 2017-10-05 | 2020-10-20 | Fulcrum Therapeutics, Inc. | inibidores de quinase p38 que reduzem dux4 e expressão de gene a jusante para o tratamento de fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
CN110590839B (zh) * | 2018-06-13 | 2022-04-05 | 四川海思科制药有限公司 | 一种乐伐替尼衍生物及制备方法和用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3629301A (en) | 1969-10-24 | 1971-12-21 | Du Pont | 3 3-difluoro-2-substituted steroids and their preparation |
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
PL187516B1 (pl) | 1996-01-11 | 2004-07-30 | Smithkline Beecham Corp | Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
IL132736A0 (en) | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
BR9913654A (pt) | 1998-08-28 | 2001-11-27 | Scios Inc | Inibidores de p-38alfa quinase |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
WO2001014378A1 (fr) | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2? |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
CZ20012494A3 (cs) | 1999-11-10 | 2001-10-17 | Ortho-Mcneil Pharmaceutical, Inc. | Substituované 2-aryl-3-(heteroaryl)-imidazo[1,2-a]Pyrimidiny, způsob přípravy těchto sloučenin a farmaceutické kompozice obsahující tyto sloučeniny |
US6756376B1 (en) | 1999-11-15 | 2004-06-29 | Shionogi & Co., Ltd. | Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities |
US6376548B1 (en) | 2000-01-28 | 2002-04-23 | Rohm And Haas Company | Enhanced propertied pesticides |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
JP2005529890A (ja) | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6951859B2 (en) | 2002-08-02 | 2005-10-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
BRPI0407282A (pt) * | 2003-02-05 | 2006-01-31 | Bristol Myers Squibb Co | Processo para preparação de inibidores de pirrolotriazina cinase |
US7265140B2 (en) | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
WO2007138381A2 (en) | 2005-10-14 | 2007-12-06 | Targanta Therapeutics Inc. | Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections |
JP2009535295A (ja) * | 2006-03-07 | 2009-10-01 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なピロロトリアジンアニリンプロドラッグ化合物 |
-
2007
- 2007-03-05 JP JP2008558486A patent/JP2009535295A/ja active Pending
- 2007-03-05 AU AU2007223342A patent/AU2007223342A1/en not_active Abandoned
- 2007-03-05 CA CA002645031A patent/CA2645031A1/en not_active Abandoned
- 2007-03-05 CN CNA2007800079168A patent/CN101395158A/zh active Pending
- 2007-03-05 BR BRPI0708644-0A patent/BRPI0708644A2/pt not_active IP Right Cessation
- 2007-03-05 MX MX2008011136A patent/MX2008011136A/es not_active Application Discontinuation
- 2007-03-05 KR KR1020087021851A patent/KR20080107408A/ko not_active Application Discontinuation
- 2007-03-05 WO PCT/US2007/063250 patent/WO2007103839A2/en active Application Filing
- 2007-03-05 EP EP07757860A patent/EP2001886A2/en not_active Withdrawn
- 2007-03-05 EA EA200801945A patent/EA200801945A1/ru unknown
- 2007-03-06 US US11/682,331 patent/US7572795B2/en active Active
- 2007-03-06 PE PE2007000242A patent/PE20080139A1/es not_active Application Discontinuation
- 2007-03-07 TW TW096107889A patent/TW200804390A/zh unknown
- 2007-03-07 AR ARP070100944A patent/AR059778A1/es unknown
-
2008
- 2008-08-24 IL IL193653A patent/IL193653A0/en unknown
- 2008-08-29 ZA ZA200807459A patent/ZA200807459B/xx unknown
- 2008-08-29 NO NO20083717A patent/NO20083717L/no not_active Application Discontinuation
-
2009
- 2009-02-12 US US12/370,081 patent/US20090156555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070213300A1 (en) | 2007-09-13 |
WO2007103839A3 (en) | 2008-06-05 |
TW200804390A (en) | 2008-01-16 |
EA200801945A1 (ru) | 2009-02-27 |
EP2001886A2 (en) | 2008-12-17 |
PE20080139A1 (es) | 2008-03-10 |
JP2009535295A (ja) | 2009-10-01 |
US7572795B2 (en) | 2009-08-11 |
CA2645031A1 (en) | 2007-09-13 |
AR059778A1 (es) | 2008-04-30 |
BRPI0708644A2 (pt) | 2011-06-07 |
KR20080107408A (ko) | 2008-12-10 |
MX2008011136A (es) | 2008-09-08 |
WO2007103839A2 (en) | 2007-09-13 |
US20090156555A1 (en) | 2009-06-18 |
CN101395158A (zh) | 2009-03-25 |
IL193653A0 (en) | 2009-08-03 |
AU2007223342A1 (en) | 2007-09-13 |
ZA200807459B (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083717L (no) | Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer | |
NO20083669L (no) | 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav | |
NO20084583L (no) | Makrosykliske kinase-inhibitorer | |
NO20091265L (no) | Pyrrolopyrazin som Syk-kinase inhibitor | |
NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
NO20076066L (no) | Oksadiazolderivater som DGAT-inhibitorer | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20092710L (no) | Cyclopaminanaloger | |
NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
TW200833324A (en) | Sulfonamide derivatives | |
TNSN08191A1 (en) | Kinase inhibitors | |
NO20073416L (no) | Indoler nyttig i behandlingen av inflammasjon | |
TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
TNSN08407A1 (en) | Organic compounds | |
TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
NO20076054L (no) | Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
CR20120053A (es) | Compuestos y metodos inhibidores de jak de pirazolopirimidina | |
NO20091247L (no) | terapeutiske pyrazolyl tienopyridiner | |
NO20091141L (no) | Pyrido (2,3-D) pyrimidinonforbindelser og deres anvendelse som P13 inhibitorer | |
NO20090445L (no) | Cykliske 11-beta hydroksysteroid-dehydrogenase type 1 inhibitorer | |
WO2007117465A3 (en) | Indazole compounds | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |